Literature DB >> 16011583

Thrombin generation and phenotypic correlation in haemophilia A.

C P Beltrán-Miranda1, A Khan, A R Jaloma-Cruz, M A Laffan.   

Abstract

The clinical phenotype of patients with haemophilia A (HA) often differs between individuals with the same factor VIII (FVIII) gene defect (e.g. within the same family) or the same coagulant activity of FVIII (FVIII:C). We proposed that because the thrombin generation assay in platelet-poor plasma of HA patients provides more information [peak thrombin concentration, endogenous thrombin potential (ETP), rate of thrombin generation and lag-time] than a clot-based FVIII assay it might provide insight into these differences. We therefore investigated the relation between the results of the thrombin generation assay and the clinical severity in nine families with HA (23 patients with different phenotypes). We also examined the contribution of prothrombotic risk factors: (FV Leiden G1691A and prothrombin G20210A), the coagulant activity of FVIII and tissue factor (5'UTR) polymorphisms. Our data detect marked differences between individuals but these did not correlate with the reported clinical phenotype. These differences were also reflected in a marked difference in response to the therapeutic amounts of FVIII. This might account for differences in amounts of treatment consumption. Reduced peak and possibly rate of thrombin generation, rather than FVIII:C or ETP appear to represent the critical defects in FVIII-deficient plasma. We suggest that the analysis of parameters in thrombin generation is a useful tool to detect bleeding tendency in HA but not to predict the modulation of the haemorrhagic tendency in patients within families. However the presence of the other factors such as vessel wall components, protein C and platelets might need to be incorporated into this system.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16011583     DOI: 10.1111/j.1365-2516.2005.01107.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  21 in total

1.  A membrane-based microfluidic device for controlling the flux of platelet agonists into flowing blood.

Authors:  Keith B Neeves; Scott L Diamond
Journal:  Lab Chip       Date:  2008-04-03       Impact factor: 6.799

2.  Thrombin generation and bleeding in haemophilia A.

Authors:  K E Brummel-Ziedins; M F Whelihan; M Gissel; K G Mann; G E Rivard
Journal:  Haemophilia       Date:  2009-06-26       Impact factor: 4.287

3.  An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia.

Authors:  Alfica Sehgal; Scott Barros; Lacramioara Ivanciu; Brian Cooley; June Qin; Tim Racie; Julia Hettinger; Mary Carioto; Yongfeng Jiang; Josh Brodsky; Harsha Prabhala; Xuemei Zhang; Husain Attarwala; Renta Hutabarat; Don Foster; Stuart Milstein; Klaus Charisse; Satya Kuchimanchi; Martin A Maier; Lubo Nechev; Pachamuthu Kandasamy; Alexander V Kel'in; Jayaprakash K Nair; Kallanthottathil G Rajeev; Muthiah Manoharan; Rachel Meyers; Benny Sorensen; Amy R Simon; Yesim Dargaud; Claude Negrier; Rodney M Camire; Akin Akinc
Journal:  Nat Med       Date:  2015-04-13       Impact factor: 53.440

4.  Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A.

Authors:  T J Girard; N M Lasky; K Grunz; G J Broze
Journal:  J Thromb Haemost       Date:  2018-12-16       Impact factor: 5.824

5.  A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A.

Authors:  Tomoko Matsumoto; Keiji Nogami; Kenichi Ogiwara; Midori Shima
Journal:  Int J Hematol       Date:  2009-11-25       Impact factor: 2.490

Review 6.  Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives.

Authors:  Guy Young; Benny Sørensen; Yesim Dargaud; Claude Negrier; Kathleen Brummel-Ziedins; Nigel S Key
Journal:  Blood       Date:  2013-01-14       Impact factor: 22.113

Review 7.  Empirical and theoretical phenotypic discrimination.

Authors:  K E Brummel-Ziedins; T Orfeo; F R Rosendaal; A Undas; G E Rivard; S Butenas; K G Mann
Journal:  J Thromb Haemost       Date:  2009-07       Impact factor: 5.824

8.  Blood product support for delivery in severe factor X deficiency: the use of thrombin generation to guide therapy.

Authors:  Joost J van Veen; Kingsley K Hampton; Rhona Maclean; Fiona Fairlie; Michael Makris
Journal:  Blood Transfus       Date:  2007-11       Impact factor: 3.443

9.  Prothrombin conversion is accelerated in the antiphospholipid syndrome and insensitive to thrombomodulin.

Authors:  Romy M W Kremers; Stéphane Zuily; Hilde Kelchtermans; Tessa C Peters; Saartje Bloemen; Véronique Regnault; H Coenraad Hemker; Philip G de Groot; Denis Wahl; Bas de Laat
Journal:  Blood Adv       Date:  2018-06-12

10.  Monitoring rFVIII prophylaxis dosing using global haemostasis assays.

Authors:  M A Al Hawaj; E J Martin; J Venitz; J C Barrett; J G Kuhn; M E Nolte; D F Brophy
Journal:  Haemophilia       Date:  2013-03-19       Impact factor: 4.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.